_:nc5dedf158f8d404a922976d48cbc88bcxb0
<http://schema.org/image>
<https://ml.globenewswire.com/media/c293ce9b-e9d6-4729-ad95-f3ddf01f3791/small/affimed-logo-jpg.jpg>
<https://stocks.observer-reporter.com/observerreporter/article/gnwcq-2023-5-23-affimed-announces-ind-clearance-for-a-phase-2-clinical-trial-investigating-afm13-and-ab-101-combination-therapy>